The centre will focus on ‘targeted protein degradation’ – one of the hottest and most promising areas in drug discovery. Scientists aim to hijack normal process of protein destruction to wipe out cancer proteins that traditional targeted drugs cannot block.

A new incubator and collaboration space for innovative life-science companies whose work is relevant to cancer is opening its doors at The London Cancer Hub in Sutton, south London.

Scientists at The Institute of Cancer Research, London, are working with the Cambridge-based immuno-oncology company Crescendo Biologics on its development of a potential ‘next generation’ immunotherapy.